Form 4: KalVista Pharmaceuticals Officer Paul K. Audhya Reports Stock Transactions

Chief Medical Officer Paul K. Audhya of KalVista Pharmaceuticals reports the vesting of restricted stock units and performance stock units, along with sales to cover tax obligations.

Summary

• On February 17, 2025, Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, exercised restricted stock units (RSUs) and performance stock units (PSUs), receiving 6,447 shares of common stock.
• On February 18, 2025, Audhya sold 3,125 shares of common stock at a price of $9.8242 per share.
• These sales were to cover tax withholding obligations related to the vesting of the RSUs and PSUs.
• Following these transactions, Audhya directly owns 100,334 shares of KalVista Pharmaceuticals common stock and 24,178 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine stock transactions by an officer to cover tax obligations, without indicating any significant positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring compliance with SEC regulations.
• Similar filings are common among pharmaceutical companies like BioCryst Pharmaceuticals and Ionis Pharmaceuticals, where stock-based compensation is a significant part of executive pay.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to tax obligations and do not represent a significant change in the officer's holdings.

Key Dates

Keywords

Form 4, KalVista Pharmaceuticals, Paul K. Audhya, Stock Sale, Restricted Stock Units, Performance Stock Units, Beneficial Ownership, Officer Transactions